On Sept. 9, 2020, Merck announced announced that two Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the companyﾒs investigational 15-valent pneumococcal conjugate vaccine, met their primary immunogenicity objectives.

PNEU-TRUE (V114-020), in healthy adults 50 years of age or older, V114 met its primary immunogenicity objective demonstrating equivalent immune response across all 15 serotypes for three different lots of V114.